Related Experiment Video

Updated: Aug 6, 2026

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Comparative promoter analysis of doxorubicin resistance-associated genes suggests E47 as a key regulatory element

András Gyorffy1, Barna Vásárhelyi, Dominika Szöke

  • 1Second Department of Internal Medicine, Semmelweis University Budapest, Szenkirdlyi u. 46, H-1085, Budapest, Hungary.

Anticancer Research
|August 5, 2006
PubMed

Insights

This study investigated transcription factors (TF) involved in doxorubicin resistance. Researchers found that the E47 TF binding site was significantly over-represented, suggesting its role in chemoresistance.

Area of Science:

  • Molecular Biology
  • Genomics
  • Cancer Research

Background:

  • Chemoresistance, particularly to doxorubicin, is a significant challenge in cancer treatment.
  • Gene expression alterations, including upregulation or downregulation, are often linked to chemoresistance.
  • Regulatory transcription factors (TF) play a crucial role in controlling gene expression.

Purpose of the Study:

  • To identify transcription factors (TF) potentially involved in doxorubicin resistance.
  • To investigate the over-representation of TF-binding sites (TFBSs) in genes associated with doxorubicin resistance.

Main Methods:

  • A data warehouse of 52 genes linked to doxorubicin resistance was created.
  • Promoter sequences for 45 genes were retrieved from genomic databases.
  • The TOUCAN tool (MotifScanner and statistics tool) was used to analyze TFBSs against the TRANSFAC database and a background model.

Main Results:

  • Analysis revealed a significantly over-represented TFBS for E47 (p=0.00024).
  • The prevalence of the E47 TFBS was 0.2 compared to a background prevalence of 8.19E-6.

Conclusions:

  • The transcription factor E47 is hypothesized to contribute to doxorubicin resistance.
  • Identifying key TFs like E47 could lead to novel therapeutic strategies for overcoming chemoresistance.

Related Concept Videos

The Eukaryotic Promoter Region02:40

The Eukaryotic Promoter Region

The eukaryotic promoter region is a segment of DNA located upstream of a gene. It contains an RNA polymerase binding site, a transcription start site, and several cis-regulatory sequences.  The proximal promoter region is located in the vicinity of the gene and has cis-regulatory sequences and the core promoter. The core promoter is the binding site for RNA polymerase and is usually located between -35 and +35 nucleotides from the transcription start site. The distal promoter regions are...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...